Strategy to prevent the progression of enterohemorrhagic Escherichia coli O157 infection to hemolytic uremic syndrome.
Takeda
T
T
Department of Infectious Diseases Research, National Children's Medical Research Center, Tokyo, Japan.
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D002648:Child; D004927:Escherichia coli Infections / Q000150:complications* / Q000188:drug therapy / Q000628:therapy; D019453:Escherichia coli O157 / Q000276:immunology; D005578:Fosfomycin / Q000627:therapeutic use; D006463:Hemolytic-Uremic Syndrome / Q000175:diagnosis / Q000188:drug therapy / Q000517:prevention & control*; D006801:Humans; D007564:Japan; D017646:Organosilicon Compounds / Q000627:therapeutic use; D012307:Risk Factors; D011795:Surveys and Questionnaires; D014312:Trisaccharides / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D000911:Antibodies, Monoclonal; D017646:Organosilicon Compounds; C119238:SYNSORB Pk; D014312:Trisaccharides; D005578:Fosfomycin